HK Innoen Presents 'K-CAB' Clinical Results at Korea's Largest Gastroenterology Conference

Presentation of Latest Research Results at KDDW 2023

HK inno.N announced on the 20th that it participated in the '7th Korea Digestive Disease Week 2023 (KDDW 2023)' held from the 16th to the 18th and presented key clinical results of K-CAB (active ingredient: Tegoprazan).

Professor Shin Cheol-min of the Department of Gastroenterology at Bundang Seoul National University Hospital is presenting the research results of K-CAB at the 7th International Gastroenterology Conference of the Korea Digestive Disease Week 2023 (KDDW 2023) Luncheon Symposium.
[Photo by HK Innoen]

KDDW 2023 is the largest international academic conference in Korea, hosted by the Korean Society of Gastroenterology and jointly organized by eight domestic digestive disease-related societies.

The studies presented this time include four main ones: ▲a multicenter phase 4 clinical trial confirming the healing rate after 2 and 4 weeks of K-CAB tablet administration in patients with erosive reflux disease (ERD) ▲a phase 3 clinical trial evaluating the safety and efficacy of K-CAB tablets as maintenance therapy in patients with endoscopically confirmed healing of erosive reflux disease ▲a real-world data study comparing the incidence of depression during K-CAB tablet administration versus proton pump inhibitors (PPIs) ▲and a study confirming the efficacy of K-CAB tablets in patients with functional dyspepsia (FD).

The study on 'Healing rate after short-term administration of K-CAB tablets in patients with erosive reflux disease' was led by Professor Seok-Chae Choi of the Department of Gastroenterology at Wonkwang University Hospital and orally presented by Professor Cheol-Min Shin of the Department of Gastroenterology at Seoul National University Bundang Hospital. The study confirmed the healing rate after administering K-CAB 50 mg for 2 and 4 weeks, demonstrating non-inferiority compared to the control group receiving PPI.

The study also examined changes in healing rates according to symptom severity and genotype. PPIs showed differences in healing rates depending on the severity of esophagitis symptoms and CYP2C19 genotype. In contrast, K-CAB, a potassium-competitive acid blocker (P-CAB), showed excellent healing rates regardless of moderate or higher esophagitis or CYP2C19 genotype. It also demonstrated rapid action and effectiveness in relieving heartburn symptoms.

Results were also presented from a study confirming the safety and efficacy of K-CAB tablets in maintenance therapy for patients with endoscopically confirmed healing of erosive reflux disease. In this study, administration of K-CAB 25 mg for up to 6 months maintained therapeutic effects and confirmed safety during long-term use. Notably, in maintenance therapy for patients with moderate or higher severity, K-CAB showed superior effects compared to the PPI group, with efficacy regardless of CYP2C19 genotype.

Two poster presentations were also conducted. Professor Jun-Sung Kim of the Department of Gastroenterology at Incheon St. Mary's Hospital and Professor Sung-Hwan Kim of the Department of Psychiatry at Yeouido St. Mary's Hospital revealed a study on 'K-CAB tablets and depression risk' using data from the Health Insurance Review and Assessment Service. This study compared the incidence of depression between users of K-CAB 50 mg and PPI drugs, confirming the safety of K-CAB regarding depression during both short- and long-term use. The results showed that the risk of developing depression was 2.18 times higher in the PPI group compared to the K-CAB group, and 2.11 times higher in long-term users of 180 days or more.

The study on 'Efficacy of K-CAB tablets in patients with functional dyspepsia (FD),' led by Professor Young-Hoon Yoon of the Department of Gastroenterology at Gangnam Severance Hospital, was presented as a poster by Professor Cheol-Woong Heo of the Department of Gastroenterology at Yongin Severance Hospital. This study assessed the overall improvement of dyspepsia symptoms after administration of K-CAB 50 mg in patients with functional dyspepsia. High symptom improvement rates of 86.7% after 8 weeks and 74.6% after 4 weeks of treatment were observed, with greater symptom improvement in patients with both functional dyspepsia and gastroesophageal reflux disease.

Dalwon Kwak, CEO of HK inno.N, stated, "K-CAB is a flagship product leading a paradigm shift in treatment, and we continuously participate in major domestic and international academic conferences to share the latest research results. We will continue to enhance differentiated competitiveness as a domestic new drug through ongoing research and development."

Meanwhile, since its launch in 2019, K-CAB has recorded sales of 478.8 billion KRW as of October, maintaining the number one position in the domestic market for four consecutive years.

This content was produced with the assistance of AI translation services.